FDA's Biosimilars Meeting Management Should Improve After Reorg In New Drug Office

 
• By Sue Sutter
  
Football
The FDA met most of its performance goals under the first year of the BsUFA II agreement. • Source: Shutterstock

More from Biosimilars

More from Biosimilars & Generics